Marc Montana, Pierre Verhaeghe, Caroline Ducros, Thierry Terme, Patrice Vanelle, Pascal Rathelot
文献索引：Therapie. 65(6) , 533-41, (2010)
全文：HTML全文
Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to which formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.© 2010 Société Française de Pharmacologie et de Thérapeutique.
